1256 related articles for article (PubMed ID: 19898223)
1. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
2. Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases.
Bennett JA; Morales-Oyarvide V; Campbell S; Longacre TA; Oliva E
Am J Surg Pathol; 2016 May; 40(5):656-63. PubMed ID: 26813747
[TBL] [Abstract][Full Text] [Related]
3. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic analysis with immunohistochemistry for DNA mismatch repair protein expression in synchronous primary endometrial and ovarian cancers.
Kobayashi Y; Nakamura K; Nomura H; Banno K; Irie H; Adachi M; Iida M; Umene K; Nogami Y; Masuda K; Kisu I; Ueki A; Yamagami W; Kataoka F; Hirasawa A; Tominaga E; Susumu N; Aoki D
Int J Gynecol Cancer; 2015 Mar; 25(3):440-6. PubMed ID: 25695547
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
Backes FJ; Leon ME; Ivanov I; Suarez A; Frankel WL; Hampel H; Fowler JM; Copeland LJ; O'Malley DM; Cohn DE
Gynecol Oncol; 2009 Sep; 114(3):486-90. PubMed ID: 19515405
[TBL] [Abstract][Full Text] [Related]
7. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.
Köbel M; Tessier-Cloutier B; Leo J; Hoang LN; Gilks CB; Soslow RA; Delair D; Stewart CJR; Lee CH
Int J Gynecol Pathol; 2017 Nov; 36(6):555-561. PubMed ID: 28114191
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.
Lu FI; Gilks CB; Mulligan AM; Ryan P; Allo G; Sy K; Shaw PA; Pollett A; Clarke BA
Int J Gynecol Pathol; 2012 Nov; 31(6):524-31. PubMed ID: 23018216
[TBL] [Abstract][Full Text] [Related]
9. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
10. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
12. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
[TBL] [Abstract][Full Text] [Related]
13. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
14. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas.
Bennett JA; Pesci A; Morales-Oyarvide V; Da Silva A; Nardi V; Oliva E
Am J Surg Pathol; 2019 Feb; 43(2):235-243. PubMed ID: 30256257
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.
Joehlin-Price AS; Perrino CM; Stephens J; Backes FJ; Goodfellow PJ; Cohn DE; Suarez AA
Gynecol Oncol; 2014 Apr; 133(1):43-7. PubMed ID: 24444820
[TBL] [Abstract][Full Text] [Related]
17. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
18. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.
Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
[TBL] [Abstract][Full Text] [Related]
19. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
Long Q; Peng Y; Tang Z; Wu C
Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
[TBL] [Abstract][Full Text] [Related]
20. Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases.
Diniz G; Aktas S; Cubuk C; Ortac R; Vergin C; Olgun N
Pediatr Hematol Oncol; 2013 May; 30(4):273-84. PubMed ID: 23570624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
